

June 16, 2014



Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23

WELLESLEY, MA -- (Marketwired) -- 06/16/14 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5™ at the Seventh Annual European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on Monday, June 23.

Dr. Ellis Behnke's talk, titled "Molecular Medical Devices to Stabilize and Repair Tissue," will be held at 5:30 pm CEST in Hall Sydney of the Congress Center Basel.

"Molecular medical devices are emerging as the next evolution in medical care," said Dr. Ellis-Behnke, a founding board member of the International Society of Nanomedicine. "Among the first of its kind is AC5, which is used to rapidly stop bleeding and to stabilize tissue. Arch Therapeutics is a leader in this field and AC5 is just the first of the Company's many exciting potential applications in R&D. The use of AC5 in procedures should reduce the time it takes to control the bleeding, provide a significantly improved tool to healthcare providers and improve the environment to permit normal healing after procedures."

Dr. Terrence Norchi, CEO of Arch Therapeutics, commented, "Dr. Ellis-Behnke grabs one's attention with his insights into the future direction of medicine, and in this case, nanomedicine. His is a future worth listening to, and it is nearly upon us. It is fitting that he is speaking at this conference sponsored by the European Foundation for Clinical Medicine (CLINAM), a highly regarded organization with a clear focus on nanomedicine and nanoscience."

Dr. Ellis-Behnke discovered the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care both faster and safer. He proposed the development and commercialization of what became Arch Therapeutics' flagship product candidate, now known as AC5. Arch Therapeutics obtained the exclusive worldwide license on the relevant intellectual property, of which Dr. Ellis-Behnke is the lead inventor, from the Massachusetts Institute of Technology and focused on design and manufacturing at the nanoscale in order to bring AC5 closer to commercialization.

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop

bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Find out more at www.archtherapeutics.com.

About CLINAM

The European Foundation for Clinical Nanomedicine is a non-profit institution focused on advancing medicine to the benefit of individuals and society through the application of nanoscience. Aimed at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focused research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders.

Find out more at <http://www.clinam.org>.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.

Contact:

ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)

Email: investors@archtherapeutics.com

Website: www.archtherapeutics.com

Source: Arch Therapeutics, Inc.